Aurinia Pharmaceuticals Inc.
General ticker "AUPH" information:
- Sector: Health Care
- Industry: Biotechnology
- Capitalization: $1.8B (TTM average)
Aurinia Pharmaceuticals Inc. follows the US Stock Market performance with the rate: 47.2%.
Estimated limits based on current volatility of 1.6%: low 15.79$, high 16.31$
Factors to consider:
- Earnings expected soon, date: 2026-07-30 bmo
- Total employees count: 130 (+261.1%) as of 2024
- US accounted for 89.4% of revenue in the fiscal year ended 2024-12-31
- Top business risk factors: Dependence on LUPKYNIS, Clinical trial failure, Regulatory and compliance, Patent risks, Inability to raise capital
- Price in estimated range
- Earnings for 3 months up through Q1 exceed our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2025-12-31 to 2027-12-31
- 2025-12-31 to 2026-12-31 estimated range: [10.59$, 18.90$]
- 2026-12-31 to 2027-12-31 estimated range: [10.17$, 18.28$]
Financial Metrics affecting the AUPH estimates:
- Positive: with PPE of 19.8 at the end of fiscal year the price was very low
- Positive: Operating profit margin, % of 37.06 > 18.40
- Negative: -0.15 < Industry inventory ratio change (median), % of 0
- Negative: negative Industry operating income (median)
- Positive: -4.39 < Investing cash flow per share per price, % of -1.52
- Positive: Return on assets ratio (scaled to [-100,100]) of 27.65 > 6.02
- Positive: Interest expense per share per price, % of 0.20 <= 0.74
Short-term AUPH quotes
Long-term AUPH plot with estimates
Financial data
| YTD | 2023-12-31 | 2024-12-31 | 2025-12-31 |
|---|---|---|---|
| Operating Revenue | $175.51MM | $239.48MM | $283.06MM |
| Operating Expenses | $267.20MM | $244.17MM | $178.14MM |
| Operating Income | $-91.69MM | $-4.69MM | $104.91MM |
| Non-Operating Income | $14.22MM | $12.13MM | $9.24MM |
| Interest Expense | $2.77MM | $4.83MM | $4.33MM |
| R&D Expense | $49.64MM | $20.79MM | $32.51MM |
| Income(Loss) | $-77.47MM | $7.45MM | $114.16MM |
| Taxes | $0.55MM | $1.70MM | $-173.04MM |
| Net Income(Loss)* | $-78.02MM | $5.75MM | $287.20MM |
| Stockholders Equity | $377.95MM | $377.48MM | $581.33MM |
| Inventory | $39.70MM | $39.23MM | $45.69MM |
| Assets | $548.06MM | $550.64MM | $751.59MM |
| Operating Cash Flow | $-33.46MM | $44.39MM | $135.66MM |
| Capital expenditure | $0.72MM | $0.28MM | $0.25MM |
| Investing Cash Flow | $-6.71MM | $39.26MM | $-32.77MM |
| Financing Cash Flow | $-5.13MM | $-49.09MM | $-106.11MM |
| Earnings Per Share** | $-0.54 | $0.04 | $2.14 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.